Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huaier Granule for Treatment of Plasma Cell Mastitis: Multicenter Real-World Study
ChiCTR2100043086Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Feb 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of huaier granule in Plasma cell mastitis (PCM) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: EORTC QLQ-C30 quality of life score. Started Feb 2021; status: recruiting.
02
Drugs
huaier granule
03
Conditions
Plasma cell mastitis (PCM)
Beyond the preview
Go deeper on ChiCTR2100043086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043086.